---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-300388"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T09:09:40.591254+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Shattuck reports early efficacy for SL-172154 in frontline HR-MDS and TP53m AML

## Summary
- HR-MDS: 5/14 evaluable patients achieved CR; 4 achieved mCR with hematologic improvement.
- TP53m AML: 2/11 evaluable patients achieved CR; 1 patient with CRi proceeded to allo-HCT.
- Grade 3/4 AEs related to SL-172154 reported in 14% of TP53m AML and 18% of HR-MDS patients.
- Infusion-related reactions most common TEAE; no destructive anemia observed.
- Cohorts expanded; additional data expected mid-2024.

## SEC filing metadata
- accession: 0001193125-23-300388
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000119312523300388/0001193125-23-300388-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000119312523300388/d14784d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-300388
- JSON: https://secwatch.observer/filing/0001193125-23-300388.json
- Plain text: https://secwatch.observer/filing/0001193125-23-300388.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.